Loading company
Macrogenics Inc.
MGNX · Nasdaq · ·
Next earnings: November 11, 2026
$3.76-7.4%Sep 29 close
- 1M
- -9.0%
- 6M
- +36.2%
- 1Y
- +123.8%
- 5Y
- -81.8%
MGNX · Nasdaq · ·
Next earnings: November 11, 2026
$3.76-7.4%Sep 29 close
Macrogenics Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $32.8M | $6.9M | +377.97% |
| Profit | $19.5M | -$36.3M | +153.83% |
| Profit per share | $0.31 | -$0.57 | +154.39% |
| Free Cash Flow | -$41.6M | -$47.7M | +12.88% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our team delivered strong second-quarter execution: advancing our strategic priorities, strengthening our financial position, and sharpening our focus to accelerate the development of life-changing medicines for patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Inc. MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Macrogenics Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Macrogenics Inc. has no earnings call transcript available.